Key View
- We forecast stable pharmaceutical market growth in Thailand, despite the broader economic slowdown facing the market.
- The government’s focus on local production will create opportunities for domestic drugmakers, while regulatory challenges may impact market entry for foreign drugmakers.
- By 2034, the generic market segment will account for around 50% of Thailand’s pharmaceutical market.
We forecast stable pharmaceutical market growth in Thailand, despite the broader economic slowdown facing the market. According to our Country Risk team, Thailand’s real GDP growth slowed down from 3.2% y-o-y in Q4 2024 to 3.1% in Q1 2025. In June 2025, despite the restrained economic growth, Thailand’s House of Representatives approved the fiscal year 2026 budget, which includes THB265bn (USD8.1bn) allocation to the National Health Security Office (NHSO), highlighting the government’s priority to strengthen the national healthcare and ensure broad access to medical services. The NHSO will use the budget to expand the National Essential Medicines List to include advanced treatments and launch public health campaigns such as ‘Healthy Thais, Free from Non-Communicable Diseases’, aimed at reducing chronic disease burden. The presence of robust funds is expected to underpin the pharmaceutical sector growth. We forecast Thailand’s pharmaceutical sales will reach THB214bn (USD6.0bn) in 2024 and THB275bn (USD8.3bn) by 2029, reflecting a five-year CAGR of 5.2% in local currency terms and 6.4% in US dollar terms.
Stable Outlook for Thailand’s Pharmaceutical Sector Amid Economic Constraints and Regulatory Challenges
Thailand’s pharmaceutical sector, a crucial component of the country’s healthcare system, remains resilient despite facing economic constraints and regulatory challenges. The nation’s GDP growth has experienced fluctuations, but the pharmaceutical industry continues to hold a promising position. This stability is largely due to increasing healthcare demand propelled by an aging population and the rise of chronic diseases. Domestic manufacturers are also enhancing their capabilities, contributing to the sector’s robust outlook.
However, the industry is not without its hurdles. Regulatory challenges, such as stringent approval processes and compliance requirements, pose significant barriers. The government has been actively working on regulatory reforms to accelerate drug approvals and ensure quality standards, which are critical for bolstering investor confidence and fostering innovation. These changes aim to streamline processes and attract more investments into the sector.
Overall, Thailand’s pharmaceutical sector represents a beacon of stability. Despite economic and regulatory pressures, the industry’s adaptive strategies and government initiatives aim to navigate these challenges. The focus on innovation, coupled with reforms, places Thailand in a strong position to enhance its pharmaceutical landscape, ensuring continued growth and development.
